Literature DB >> 23208023

Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases.

Takaiko Yoshino1, Takeo Fukuchi, Tetsuya Togano, Masaaki Seki, Hiroko Ikegaki, Haruki Abe.   

Abstract

PURPOSE: To investigate the incidence of adverse effects on eyelids and eyelashes related to treatment with prostaglandin analogs (PGAs) in patients who apply the medication in only one eye.
METHODS: A clinical examination of 39 glaucoma patients treated for over 3 months continuously in one eye with one of four PGAs. Face photographs were used to judge adverse effects of PGA treatment on eyelids and eyelashes of the treated eyes by comparing them with the eyelids and eyelashes of the contralateral eyes. Each of three examiners then calculated scores for the eyelids and eyelashes by counting how many adverse effects were present (out of five possible effects for eyelids and two for eyelashes). The findings for the eyelids or eyelashes were considered "positive" if two or more examiners judged that at least one adverse effect was present.
RESULTS: Thirty-five (89.7 %) patients were judged to have positive eyelid findings and 37 (94.9 %) patients were judged to have positive eyelash findings. There was a significant correlation between the period of PGA administration and eyelid score (P = 0.0218).
CONCLUSION: There was a high incidence of adverse effects caused by PGAs in the eyelids and eyelashes. The frequency of adverse effects of the eyelid seemed to increase as the use of PGAs was prolonged. The cosmetic complications caused by PGA use should be considered, and patients should be informed of them in advance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23208023     DOI: 10.1007/s10384-012-0199-3

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  18 in total

1.  Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost.

Authors:  Makoto Aihara; Shiroaki Shirato; Rei Sakata
Journal:  Jpn J Ophthalmol       Date:  2011-09-28       Impact factor: 2.447

2.  [Adverse reaction after use of latanoprost in Japanese glaucoma patients].

Authors:  Kenji Inoue; Masato Wakakura; Jiro Inoue; Hiroshi Matsuo; Takeshi Hara; Goji Tomita
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2006-08

3.  Periorbital changes associated with topical bimatoprost.

Authors:  Theodoros Filippopoulos; Jayter S Paula; Nurhan Torun; Mark P Hatton; Louis R Pasquale; Cynthia L Grosskreutz
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2008 Jul-Aug       Impact factor: 1.746

4.  Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients.

Authors:  T Chiba; K Kashiwagi; S Kogure; K Abe; T Shibuya; M Furuichi; H Iijima; S Tsukahara
Journal:  J Glaucoma       Date:  2001-10       Impact factor: 2.503

5.  Clinical course of bimatoprost-induced periocular skin changes in Caucasians.

Authors:  Manali Doshi; Deepak P Edward; Smajo Osmanovic
Journal:  Ophthalmology       Date:  2006-08-28       Impact factor: 12.079

6.  Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.

Authors:  Juwan Park; Hyun Kyung Cho; Jung-Il Moon
Journal:  Jpn J Ophthalmol       Date:  2011-02-18       Impact factor: 2.447

7.  [Orbital fat atrophy in glaucoma patients treated with topical bimatoprost--can bimatoprost cause enophthalmos?].

Authors:  C Tappeiner; B Perren; M E Iliev; B E Frueh; D Goldblum
Journal:  Klin Monbl Augenheilkd       Date:  2008-05       Impact factor: 0.700

8.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

9.  Long-term effects of latanoprost monotherapy on intraocular pressure in Japanese glaucoma patients.

Authors:  Kenji Kashiwagi; Toyoaki Tsumura; Shigeo Tsukahara
Journal:  J Glaucoma       Date:  2008-12       Impact factor: 2.503

10.  A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension.

Authors:  I Goldberg; X-Y Li; P Selaru; D Paggiarino
Journal:  Eur J Ophthalmol       Date:  2008 May-Jun       Impact factor: 2.597

View more
  10 in total

1.  Floppy eyelid syndrome and ectropion improvement after 1 month of 0.03% Bimatoprost topical therapy.

Authors:  Alessandra De Gregorio; Emilio Pedrotti; Giulia Stevan; Andrea Scala; Alessandro Lambiase; Simonetta Morselli
Journal:  Am J Ophthalmol Case Rep       Date:  2020-09-23

Review 2.  Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension.

Authors:  Gillian M Keating
Journal:  Clin Drug Investig       Date:  2016-06       Impact factor: 2.859

Review 3.  In Vivo Analysis of Prostaglandins-induced Ocular Surface and Periocular Adnexa Modifications in Patients with Glaucoma.

Authors:  Silvio DI Staso; Luca Agnifili; Sara Cecannecchia; Angela DI Gregorio; Marco Ciancaglini
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

4.  The action of prostaglandins on ciliary hypertrichosis: a case report of pachydermoperiostosis.

Authors:  Fabiana P Zarur; Luiza Vf d'Almeida; Anna Beatriz C Novellino; Maria Fernanda Dg Reis
Journal:  Int J Trichology       Date:  2014-01

5.  Prostaglandin-associated periorbitopathy in latanoprost users.

Authors:  Shunsuke Nakakura; Minamai Yamamoto; Etsuko Terao; Nozomi Nagatomi; Naoko Matsuo; Yausko Fujisawa; Yuki Fujio; Hitoshi Tabuchi; Yoshiaki Kiuchi
Journal:  Clin Ophthalmol       Date:  2014-12-30

6.  Periorbital changes associated with prostaglandin analogs in Korean patients.

Authors:  Hee Weon Kim; Youn Joo Choi; Kyung Wha Lee; Min Joung Lee
Journal:  BMC Ophthalmol       Date:  2017-07-17       Impact factor: 2.209

7.  Open-label pilot study to evaluate the effectiveness of topical bimatoprost on rhododendrol-induced refractory leukoderma.

Authors:  Saki Fukaya; Masahiro Kamata; Tomoko Kasanuki; Makoto Yokobori; Shintaro Takeoka; Kotaro Hayashi; Takamitsu Tanaka; Atsuko Fukuyasu; Takeko Ishikawa; Takamitsu Ohnishi; Satoshi Iimuro; Yayoi Tada; Shinichi Watanabe
Journal:  J Dermatol       Date:  2018-08-29       Impact factor: 4.005

8.  Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy.

Authors:  Tomoaki Higashiyama; Masahito Ohji
Journal:  Clin Ophthalmol       Date:  2018-11-27

9.  Decreased orbital fat and enophthalmos due to bimatoprost: Quantitative analysis using magnetic resonance imaging.

Authors:  Tomoaki Higashiyama; Takayuki Minamikawa; Masashi Kakinoki; Osamu Sawada; Masahito Ohji
Journal:  PLoS One       Date:  2019-03-27       Impact factor: 3.240

10.  Orbital Fat Volume After Treatment with Topical Prostaglandin Agonists.

Authors:  Jessica Y Chen; Alan Le; Joseph Caprioli; JoAnn A Giaconi; Kouros Nouri-Mahdavi; Simon K Law; Laura Bonelli; Anne L Coleman; Joseph L Demer
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-05-11       Impact factor: 4.799

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.